Ischemic stroke market Research Report- Forecast till 2027

Ischemic Stroke Market research report: by diagnosis (CT, MRI, carotid ultrasound, cerebral angiography), drug class (tissue plasminogen activator, anticoagulant, antiplatelet, antihypertensive), surgery, end user – forecast till 2027

ID: MRFR/MED/3980-HCR | February 2021 | Region: Global | 120 pages

Ischemic Stroke Market Scenario:


Ischemic strokes occur as a result of an obstruction within a blood vessel supplying blood to the brain. The underlying condition of this type of obstruction is the development of fat deposits lining the vessel walls, which is known as atherosclerosis. According to the World Health Organization (WHO), stroke accounts for around 17 million deaths annually. As per the Centers for Disease Control and Prevention (CDC), stroke leads to 1 out of every 20 deaths costing around USD 34 billion each year in the U.S. Higher rates of mortality associated with strokes highlight an impending need for innovative drugs and diagnostic devices.


The key strategies adopted by leading industry players incldues new product launches and collaborations. For instance, in April 2016, the novel TransCarotid Artery Revascularization (TCAR) procedure launched by Silk Road Medical, Inc, received FDA approval. This minimally invasive technique is designed to access the common carotid artery. Moreover, in March, 2015, WATCHMAN, a closure device designed to prevent stroke in patients with atrial fibrillation received FDA approval.


Rising cases of ischemia stroke are driving the demand for surgical procedures in stroke treatment. Increasing demand for minimally invasive procedures and advancements in surgical procedures are the key factors boosting the growth of the ischemic stroke market. High cost of the surgical procedures and excessive usage of medication for the treatment of ischemic stroke are hindering the market growth.


The ischemic stroke market is expected to grow at a CAGR of approximately 8.3% during the forecast period 2017-2023.


Research Methodology:


 Research Methodology


Sources: Annual reports, Press release, White paper, and Company presentation


Intended Audience:



  • Ischemic Stroke Drug Suppliers

  • Ischemic Stroke Drug Manufacturers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Segmentation:


The ischemic stroke is segmented on the basis of diagnosis, drug class, surgery and end-users.


On the basis of the diagnosis, the ischemic stroke market is segmented into Computed Tomography (CT), Magnetic resonance imaging (MRI), carotid ultrasound, cerebral angiography, electrocardiography, echocardiography, and others.


On the basis of the drug class, the ischemic stroke market is segmented into tissue plasminogen activator, anticoagulant, antiplatelet, antihypertensive, and others


On the basis of the surgery, the ischemic stroke market is segmented into carotid endarterectomy, angioplasty, and endovascular mechanical thrombectomy


On the basis of the end-user, the ischemic stroke market is segmented into hospitals & clinics, medical institutes, research organization, and others.


Regional Analysis:                     


The ischemic stroke market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.


The Americas has emerged as the largest market for the global ischemic stroke market owing to the favorable government initiatives, technological innovations, and increasing demand for ischemic stroke products. According to the American Heart Association, ischemic stroke is among the top three causes of death in the U.S. and Canada, nearly 795,000 patients suffering from strokes are treated in the 2014.


Europe is the second largest global ischemic stroke market owing to the advancements in the surgical devices technology along with the rising occurrence of acute ischemia stroke cases among the patients. In the European Union, over 31 million people are living with diabetes aged between 20 and 79. This signifies an average diabetes prevalence rate of 8.6% of the adult population. Some other factors driving the ischemic stroke market includes the growing percentage of diabetes mellitus population mainly in the developed countries of Europe


Asia Pacific is anticipated to unfold as the most promising market for the global ischemic stroke market owing to increasing prevalence of stroke cases in this region. China and India are considered as a big market for ischemic stroke within the forecast period. Manufacturers are expanding their operations in Asia Pacific region as these regions hold immense potential for the ischemic stroke market growth.


The Middle East region is expected to grow at a faster rate due to the factors such as the extensive development of healthcare infrastructure and growing emphasis on research and development in the healthcare sector.


Key Players:


The emergence of new and cost-effective medication options for the treatment of ischemic stroke could open up new opportunities to the new players in the global ischemic stroke market. Additionally, emerging markets, such as India and China, could also open new opportunities to new players.


Some of key the players in the ischemic stroke market are Abbott Laboratories (U.S.), Medtronic plc (U.S.), Boston Scientific Corporation (U.S.), Cordis Corporation (U.S.),  Koninklijke Philips N.V. (Netherland), GE Healthcare (U.S.), Stryker Corporation (U.S.), Genentech, Inc. (U.S.), Merck & Co., Inc. (U.S.),  Bayer AG (Germany), Boehringer Ingelheim (Germany), Sanofi (France), Covidien plc (Ireland), Philips Healthcare (U.S.), Johnson & Johnson (U.S.), Penumbra, Inc. (U.S.),  GE Healthcare (U.S.),  Siemens Healthcare (U.S.), Hitachi, Ltd (Japan), Biogen (U.S.), Daiichi Sankyo (U.S.), Pfizer Inc. (U.S.), and others



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   8.3% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, Drug Class, Surgery and End-Users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Abbott Laboratories (U.S.), Medtronic plc (U.S.), Boston Scientific Corporation (U.S.), Cordis Corporation (U.S.), Koninklijke Philips N.V. (Netherland), GE Healthcare (U.S.), Stryker Corporation (U.S.), Genentech, Inc. (U.S.), Merck & Co., Inc. (U.S.), Bayer AG (Germany), Boehringer Ingelheim (Germany), Sanofi (France), Covidien plc (Ireland), Philips Healthcare (U.S.), Johnson & Johnson (U.S.), Penumbra, Inc. (U.S.), GE Healthcare (U.S.), Siemens Healthcare (U.S.), Hitachi, Ltd (Japan), Biogen (U.S.), Daiichi Sankyo (U.S.), Pfizer Inc. (U.S.), and others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Rising cases of ischemia stroke
  • Increasing demand for minimally invasive procedures
  • Advancements in surgical procedures

    		•


    Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Ischemic strokes occur as a result of an obstruction within a blood vessel supplying blood to the brain. The underlying condition of this type of obstruction is the development of fat deposits lining the vessel walls, which is known as atherosclerosis.

    Ischemic strokes occur as a result of an obstruction within a blood vessel supplying blood to the brain. The underlying condition of this type of obstruction is the development of fat deposits lining the vessel walls, which is known as atherosclerosis.

    Ischemic stroke market is expected to grow at a CAGR of approximately 8.3% during the forecast period 2017-2023.

    Rising cases of ischemia stroke are driving the demand for surgical procedures in stroke treatment. Increasing demand for minimally invasive procedures and advancements in surgical procedures are the key factors boosting the growth of the global ischemic stroke market.

    The Americas has emerged as the largest market for the global ischemic stroke owing to the favorable government initiatives, technological innovations, and increasing demand for ischemic stroke products.

    Some of key the players in the ischemic stroke market are Abbott Laboratories (U.S.), Medtronic plc (U.S.), Boston Scientific Corporation (U.S.), Cordis Corporation (U.S.), Koninklijke Philips N.V. (Netherland), GE Healthcare (U.S.), Stryker Corporation (U.S.), Genentech, Inc. (U.S.), Merck & Co., Inc. (U.S.), Bayer AG (Germany), Boehringer Ingelheim (Germany), Sanofi (France), Covidien plc (Ireland), Philips Healthcare (U.S.), Johnson & Johnson (U.S.), Penumbra, Inc. (U.S.), GE Healthcare (U.S.), Siemens Healthcare (U.S.), Hitachi, Ltd (Japan), Biogen (U.S.), Daiichi Sankyo (U.S.), Pfizer Inc. (U.S.), and others

    TABLE OF CONTENT


    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope Of The Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Introduction

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restrains

    4.3 Opportunities

    4.4 Challenges

    4.5 Macroeconomic Indicators

    4.6 Surgery Trends & Assessment

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power Of Suppliers

    5.1.2 Bargaining Power Of Buyers

    5.1.3 Threat Of New Entrants

    5.1.4 Threat Of Substitutes

    5.1.5 Intensity Of Rivalry

    5.2 Value Chain Analysis

    5.3 Investment Feasibility Analysis

    5.4 Pricing Analysis

    Chapter 7. Global Ischemic Stroke Market, By Diagnosis

    7.1 Introduction

    7.2 Computed Tomography (CT)

    7.3.1 Market Estimates & Forecast, 2020 – 2027

    7.3 Magnetic Resonance Imaging (MRI)

    7.3.1 Market Estimates & Forecast, 2020 – 2027

    7.4 Carotid Ultrasound

    7.4.1 Market Estimates & Forecast, 2020 – 2027

    7.5 Cerebral Angiography

    7.5.1 Market Estimates & Forecast, 2020 – 2027

    7.6 Electrocardiography

    7.7.1 Market Estimates & Forecast, 2020 – 2027

    7.8 Echocardiography

    7.8.1 Market Estimates & Forecast, 2020 – 2027

    7.4 Others

    Chapter 8. Global Ischemic Stroke Market, By Drug Class

    8.1 Introduction

    8.2 Tissue Plasminogen Activator

    8.2.1 Market Estimates & Forecast, 2020 – 2027

    8.3 Anticoagulant

    8.3.1 Market Estimates & Forecast, 2020 – 2027

    8.4 Antiplatelet

    8.4.1 Market Estimates & Forecast, 2020 – 2027

    8.5 Antihypertensive

    8.5.1 Market Estimates & Forecast, 2020 – 2027

    8.6 Others

    Chapter 9. Global Ischemic Stroke Market, By Surgery

    9.1 Introduction

    9.2 Carotid Endarterectomy

    9.2.1 Market Estimates & Forecast, 2020 – 2027

    9.3 Angioplasty

    9.3.1 Market Estimates & Forecast, 2020 – 2027

    9.4 Endovascular Mechanical Thrombectomy

    9.4.1 Market Estimates & Forecast, 2020 – 2027

    Chapter 10. Global Ischemic Stroke Market, By End User

    10.1 Introduction

    10.2 Hospitals & Clinics

    10.2.1 Market Estimates & Forecast, 2020 – 2027

    10.3 Medical Institutes

    10.3.1 Market Estimates & Forecast, 2020 – 2027

    10.4 Research Organization

    10.4.1 Market Estimates & Forecast, 2020 – 2027

    10.5 Others

    10.5.1 Market Estimates & Forecast, 2020 – 2027

    Chapter. 11 Global Ischemic Stroke Market, By Region

    11.1 Introduction

    11.2 Americas

    11.2.1 North America

    11.2.1.1 U.S.

    11.2.1.2 Canada

    11.2.2 South America

    11.3 Europe

    11.3.1 Western Europe

    11.3.1.1 Germany

    11.3.1.2 France

    11.3.1.3 Italy

    11.3.1.4 Spain

    11.3.1.5 U.K

    11.3.1.6 Rest Of Western Europe

    11.3.2 Eastern Europe

    11.4 Asia Pacific

    11.4.1 Japan

    11.4.2 China

    11.4.3 India

    11.4.4 Australia

    11.4.5 Republic Of Korea

    11.4.6 Rest Of Asia Pacific

    11.5 The Middle East & Africa

    11.5.1 United Arab Emirates

    11.5.2 Saudi Arabia

    11.5.3 Rest Of The Middle East & Africa

    Chapter 12 Company Landscape

    12.1 Introduction

    12.2 Market Share Analysis

    12.3 Key Development & Strategies

    12.3.1 Key Developments

    Chapter 13 Company Profiles

    13.1 Abbott Laboratories

    13.1.1 Company Overview

    13.1.2 Drug Class Overview

    13.1.3 Financials

    13.1.4 SWOT Analysis

    13.2 Medtronic Plc

    13.2.1 Company Overview

    13.2.2 Drug Class Overview

    13.2.3 Financial Overview

    13.2.4 Key Developments

    13.2.5 SWOT Analysis

    13.3 Boston Scientific Corporation

    13.3.1 Company Overview

    13.3.2 Drug Class Overview

    13.3.3 Financial Overview

    13.3.4 Key Development

    13.3.5 SWOT Analysis

    13.4 Cordis Corporation

    13.4.1 Company Overview

    13.4.2 Drug Class/Business Segment Overview

    13.4.3 Financial Overview

    13.4.4 Key Development

    13.4.5 SWOT Analysis

    13.5 Merck & Co., Inc.

    13.5.1 Company Overview

    13.5.2 Drug Class Overview

    13.5.3 Financial Overview

    13.5.4 Key Developments

    13.6 Koninklijke Philips N.V.

    13.6.1 Company Overview

    13.6.2 Drug Class Overview

    13.6.3 Financial Overview

    13.6.4 Key Developments

    13.7 GE Healthcare

    13.7.1 Overview

    13.7.2 Drug Class Overview

    13.7.3 Financials

    13.7.4 Key Developments

    13.7.5 SWOT Analysis

    13.8 Stryker Corporation

    13.8.1 Company Overview

    13.8.2 Drug Class/Business Segment Overview

    13.8.3 Financial Overview

    13.8.4 Key Development

    13.8.5 SWOT Analysis

    13.9 Pfizer Inc.

    13.9.1 Company Overview

    13.9.2 Drug Class Overview

    13.9.3 Financial Overview

    13.9.4 Key Developments

    13.10 Others

    Chapter 14 MRFR Conclusion

    14.1 Key Findings

    14.1.1 From CEO’s View Point

    14.1.2 Unmet Needs Of The Market

    14.2 Key Companies To Watch

    14.3 Prediction Of Pharmaceutical Industry

    Chapter 15 Appendix


    LIST OF TABLES


    Table 1 Ischemic Stroke Industry Synopsis, 2020 – 2027

    Table 2 Ischemic Stroke Market Estimates And Forecast, 2020 – 2027, (USD Million)

    Table 3 Ischemic Stroke Market By Region, 2020 – 2027, (USD Million)

    Table 4 Ischemic Stroke Market By Diagnosis, 2020 – 2027, (USD Million)

    Table 5 Ischemic Stroke Market By Drug Class, 2020 – 2027, (USD Million)

    Table 6 Ischemic Stroke Market By Surgery, 2020 – 2027, (USD Million)

    Table 7 Ischemic Stroke Market By End Users, 2020 – 2027, (USD Million)

    Table 8 North America Ischemic Stroke Market By Diagnosis, 2020 – 2027, (USD Million)

    Table 9 North America Ischemic Stroke Market By Drug Class, 2020 – 2027, (USD Million)

    Table 10 North America Ischemic Stroke Market By Surgery, 2020 – 2027, (USD Million)

    Table 11 North America Ischemic Stroke Market By End User, 2020 – 2027, (USD Million)

    Table 12 US Ischemic Stroke Market By Diagnosis, 2020 – 2027, (USD Million)

    Table 13 US Ischemic Stroke Market By Drug Class, 2020 – 2027, (USD Million)

    Table 14 US Ischemic Stroke Market By Surgery, 2020 – 2027, (USD Million)

    Table 15 US Ischemic Stroke Market By End User, 2020 – 2027, (USD Million)

    Table 16 Canada Ischemic Stroke Market By Diagnosis, 2020 – 2027, (USD Million)

    Table 17 Canada Ischemic Stroke Market By Drug Class, 2020 – 2027, (USD Million)

    Table 18 Canada Ischemic Stroke Market By Surgery, 2020 – 2027, (USD Million)

    Table 19 Canada Ischemic Stroke Market By End User, 2020 – 2027, (USD Million)

    Table 20 South America Ischemic Stroke Market By Diagnosis, 2020 – 2027, (USD Million)

    Table 21 South America Ischemic Stroke Market By Drug Class, 2020 – 2027, (USD Million)

    Table 22 South America Ischemic Stroke Market By Surgery, 2020 – 2027, (USD Million)

    Table 23 South America Ischemic Stroke Market By End User, 2020 – 2027, (USD Million)

    Table 24 Europe Ischemic Stroke Market By Diagnosis, 2020 – 2027, (USD Million)

    Table 25 Europe Ischemic Stroke Market By Drug Class, 2020 – 2027, (USD Million)

    Table 26 Europe Ischemic Stroke Market By Surgery, 2020 – 2027, (USD Million)

    Table 27 Europe Ischemic Stroke Market By End User, 2020 – 2027, (USD Million)

    Table 28 Western Europe Ischemic Stroke Market By Diagnosis, 2020 – 2027, (USD Million)

    Table 29 Western Europe Ischemic Stroke Market By Drug Class, 2020 – 2027, (USD Million)

    Table 30 Western Europe Ischemic Stroke Market By Surgery, 2020 – 2027, (USD Million)

    Table 31 Western Europe Ischemic Stroke Market By End User, 2020 – 2027, (USD Million)

    Table 32 Eastern Europe Ischemic Stroke Market By Diagnosis, 2020 – 2027, (USD Million)

    Table 33 Eastern Europe Ischemic Stroke Market By Drug Class, 2020 – 2027, (USD Million)

    Table 34 Eastern Europe Ischemic Stroke Market By Surgery, 2020 – 2027, (USD Million)

    Table 35 Eastern Europe Ischemic Stroke Market By End User, 2020 – 2027, (USD Million)

    Table 36 Asia Pacific Ischemic Stroke Market By Diagnosis, 2020 – 2027, (USD Million)

    Table 37 Asia Pacific Ischemic Stroke Market By Drug Class, 2020 – 2027, (USD Million)

    Table 38 Asia Pacific Ischemic Stroke Market By Surgery, 2020 – 2027, (USD Million)

    Table 39 Asia Pacific Ischemic Stroke Market By End User, 2020 – 2027, (USD Million)

    Table 40 The Middle East & Africa Ischemic Stroke Market By Diagnosis, 2020 – 2027, (USD Million)

    Table 41 The Middle East & Africa Ischemic Stroke Market By Drug Class, 2020 – 2027, (USD Million)

    Table 42 The Middle East & Africa Ischemic Stroke Market By Surgery, 2020 – 2027, (USD Million)

    Table 43 The Middle East & Africa Ischemic Stroke Market By End User, 2020 – 2027, (USD Million)



    LIST OF FIGURES


    Figure 1 Research Process

    Figure 2 Segmentation For Ischemic Stroke Market

    Figure 3 Segmentation Market Dynamics For Ischemic Stroke Market

    Figure 4 Global Ischemic Stroke Market Share, By Diagnosis 2020

    Figure 6 Global Ischemic Stroke Market Share, By Drug Class 2020

    Figure 7 Global Ischemic Stroke Market Share, By Surgery, 2020

    Figure 8 Global Ischemic Stroke Market Share, By End Users, 2020

    Figure 9 Global Ischemic Stroke Market Share, By Region, 2020

    Figure 10 North America Ischemic Stroke Market Share, By Country, 2020

    Figure 11 Europe Ischemic Stroke Market Share, By Country, 2020

    Figure 12 Asia Pacific Ischemic Stroke Market Share, By Country, 2020

    Figure 13 The Middle East & Africa Ischemic Stroke Market Share, By Country, 2020

    Figure 14 Global Ischemic Stroke Market: Company Share Analysis, 2020 (%)

    Figure 15 Abbott Laboratories: Key Financials

    Figure 16 Abbott Laboratories: Segmental Revenue

    Figure 17 Abbott Laboratories: Geographical Revenue

    Figure 18 Medtronic Plc: Key Financials

    Figure 19 Medtronic Plc: Segmental Revenue

    Figure 20 Medtronic Plc: Geographical Revenue

    Figure 21 Boston Scientific Corporation: Key Financials

    Figure 22 Boston Scientific Corporation: Segmental Revenue

    Figure 23 Boston Scientific Corporation: Geographical Revenue

    Figure 24 Cordis Corporation: Key Financials

    Figure 25 Cordis Corporation: Segmental Revenue

    Figure 26 Cordis Corporation: Geographical Revenue

    Figure 27 Merck & Co., Inc.: Key Financials

    Figure 28 Merck & Co., Inc.: Segmental Revenue

    Figure 29 Merck & Co., Inc.: Geographical Revenue

    Figure 30 Koninklijke Philips N.V.: Key Financials

    Figure 31 Koninklijke Philips N.V.: Segmental Revenue

    Figure 32 Koninklijke Philips N.V.: Geographical Revenue

    Figure 33 GE Healthcare: Key Financials

    Figure 34 GE Healthcare: Segmental Revenue

    Figure 35 GE Healthcare: Geographical Revenue

    Figure 36 Stryker Corporation: Key Financials

    Figure 37 Stryker Corporation: Segmental Revenue

    Figure 38 Stryker Corporation: Geographical Revenue

    Figure 39 Pfizer Inc.: Key Financials

    Figure 40 Pfizer Inc.: Segmental Revenue

    Figure 41 Pfizer Inc.: Geographical Revenue

    Bottom of Form